AmerisourceBergen to Support Commercialization of Krystal Biotech’s Gene Therapy
The U.S. Food and Drug Administration (FDA) today approved Krystal Biotech, Inc.’s VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa. As part of its agreement with Krystal Biotech, AmerisourceBergen will serve as the exclusive specialty distributor of the product. AmerisourceBergen’s commercialization support is expected to include third-party logistics, including cGMP kitting, storage and distribution of the frozen products.
“Cell and gene therapy products can transform how certain diseases are treated, offering significant promise for patients around the world. Our goal is to provide developers with access to services across the product lifecycle to simplify the commercialization process and help them achieve the outcomes they desire,” said Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. “We are thrilled to support Krystal Biotech and look forward to providing the services needed to help them drive commercial success and ensure patients have timely and reliable access to the treatment.”
Accelerating healthier futures
As healthcare advances, so must the processes that connect patients to the therapies they need. Each patient's path to treatment is unique. And because a rapidly evolving cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.
Every innovator needs a connector. We exist to connect you.